immunology

Bay Genomics, LLC is a Berkeley, CA based laboratory providing technology development for the life sciences. It helps clients develop cell models, genetic sequence analysis, cell culture work, drug testing, and proof-of-concept device development, and offers expertise in molecular biology, genetics, gene therapy, microscopy, histology, neuroscience, tissue culture, biochemistry, immunology, animal models of disease, bioinformatics, virus design, gene arrays, and sequencing. It is registered with SAM to subcontract on federal contracts and has experience

3D printinganimal models of diseasebiochemistryBioinformaticscomputer aided designgene arraysgene therapygeneticshistologyMicroscopymolecular biologyneurosciencePCB designphysiologypromoter bashingsequencingsolderingtissue culturevirus design

DIOSynVax customises vaccine antigen design to maximise protection against existing and future viruses. Its patent-protected method combines computational biology with in vitro and in vivo validation to select Vaccine Antigen Payload (VAP) candidates. The company targets high-consequence viruses including influenza, haemorrhagic fever, and coronaviruses such as SARS-CoV-2, and partners with leading organisations to advance vaccine solutions.

Artificial Intelligencecomputational biologyGenomicsin vitro validationin vivo validationpreclinical and clinical testingsynthetic biology

Eligo Bioscience is deploying in vivo gene editing technologies against microbiome targets to address diseases with high unmet needs. It has developed a first-in-class proprietary GEM (Gene Editing of the Microbiome) platform to edit the microbiome gene repertoire in vivo, and was founded by the inventors of CRISPR-based bacterial precision killing.

CRISPR-based bacterial precision killingin vivo gene editingMicrobiologyphage biologysynthetic biology

Inimmune is a clinical-stage biotech company founded in early 2016 by Drs. Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter, and a team of 11 scientists, focused on discovering and developing disease-modifying immunotherapies and next-generation vaccines. Its pipeline includes clinical-stage Toll-like receptor agonists INI-4001 (TLR7/8 agonist) and INI-2004 (TLR4 agonist) for immuno-oncology and allergy, plus innate immune agonists and antagonists as vaccine adjuvants.

clinical translationdrug formulationimmunotherapy discovery and developmentsynthetic and process chemistry

June Bio is a Copenhagen-based biotech company innovating in glycobiology, biomanufacturing, and immunology to restore mucosal health. Its journey began with discoveries in glycobiology and mucin biology at Cornell University, and it is supported by the BioInnovation Institute. June Bio was launched in 2025 by Frederik Madsen, Thomas Crouzier, and Matt DeLisa, and is developing scalable, affordable production of mucins to rebuild the body's natural mucosal defense.

biomanufacturingglycobiologyglycoengineeringmicrobial biomanufacturingscalable mucin production